» Authors » Nishanta Singh

Nishanta Singh

Explore the profile of Nishanta Singh including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 805
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Shinde V, Lombard Koen A, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al.
Hum Vaccin Immunother . 2024 Dec; 20(1):2425147. PMID: 39666396
COVID-19 remains a global public health issue and an improved understanding of vaccine performance in immunocompromised individuals, including people living with HIV (PLWH), is needed. Initial data from the present...
2.
Garrett N, Reddy T, Yende-Zuma N, Takalani A, Woeber K, Bodenstein A, et al.
PLOS Glob Public Health . 2024 Dec; 4(12):e0003260. PMID: 39636838
Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after...
3.
Bekker L, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, et al.
N Engl J Med . 2024 Jul; 391(13):1179-1192. PMID: 39046157
Background: There are gaps in uptake of, adherence to, and persistence in the use of preexposure prophylaxis for human immunodeficiency virus (HIV) prevention among cisgender women. Methods: We conducted a...
4.
Malahleha M, Laher F, Dilraj A, Smith P, Gray G, Grove D, et al.
AIDS Behav . 2023 Mar; 27(9):3027-3037. PMID: 36929319
In South Africa, HIV acquisition risk has been studied less in people assigned male at birth. We studied the associations between risk behaviors, clinical features and HIV incidence amongst males...
5.
Chimukuche R, Kawuma R, Mahapa N, Mkhwanazi S, Singh N, Siva S, et al.
BMC Health Serv Res . 2022 Nov; 22(1):1336. PMID: 36357877
Background: PrEP literacy is influenced by many factors including the types of information available and how it is interpreted. The level of PrEP literacy may influence acceptability and uptake. Methods:...
6.
Asare K, Andine T, Naicker N, Dorward J, Singh N, Spooner E, et al.
Clin Infect Dis . 2022 Oct; 76(5):881-889. PMID: 36250382
Background: Alternative approaches to syndromic management are needed to reduce rates of sexually transmitted infections (STIs) in resource-limited settings. We investigated the impact of point-of-care (POC) versus central laboratory-based testing...
7.
Moodie Z, Dintwe O, Sawant S, Grove D, Huang Y, Janes H, et al.
J Infect Dis . 2022 Jun; 226(2):246-257. PMID: 35758878
Background: The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates...
8.
Madhi S, Moodley D, Hanley S, Archary M, Hoosain Z, Lalloo U, et al.
Lancet HIV . 2022 Apr; 9(5):e309-e322. PMID: 35489376
Background: There is a paucity of data on COVID-19 vaccines in people living with HIV-1, who could be at increased risk of severe illness and death from COVID-19. We evaluated...
9.
Delany-Moretlwe S, Hughes J, Bock P, Ouma S, Hunidzarira P, Kalonji D, et al.
Lancet . 2022 Apr; 399(10337):1779-1789. PMID: 35378077
Background: Oral pre-exposure prophylaxis has been introduced in more than 70 countries, including many in sub-Saharan Africa, but women experience considerable barriers to daily pill-taking, such as stigma, judgement, and...
10.
Garcia M, Luecke E, Mayo A, Scheckter R, Ndase P, Kiweewa F, et al.
BMC Public Health . 2021 Nov; 21(1):2041. PMID: 34749675
Background: Low adherence to investigational products can negatively impact study outcomes, limiting the ability to demonstrate efficacy. To continue advancing potential new HIV prevention technologies, efforts are needed to improve...